Brief: Veradermics Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Vdphl01 For Male Pattern Hair Loss
09/02/2026 14:52
Feb 9 (Reuters) - Veradermics Inc MANE.N: VERADERMICS COMPLETES ENROLLMENT IN SECOND PIVOTAL PHASE 3 CLINICAL TRIAL OF VDPHL01 FOR MALE PATTERN HAIR LOSS VERADERMICS INC - TOPLINE DATA FROM '302' TRIAL EXPECTED FIRST HALF 2026 Source text: ID:nBw6hbsB1a Further company coverage: MANE.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Veradermics, Incorporated
See all newsVeradermics' oral hair-loss drug shown to boost hair growth in late-stage study (updated)
Brief: Veradermics’ Oral Vdphl01 Achieved Early, Consistent, And Robust Hair Growth In Positive Phase 3 ‘304’ Clinical Trial In Male Pattern Hair Loss
Veradermics' oral hair-loss drug shown to boost hair growth in late-stage study
Focus: Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
Veradermics Q2 net loss widens on higher expenses